551 Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers
Main Authors: | Paolo A Ascierto, Giovanni Abbadessa, Brigitte Demers, PARK John, Adyb Baakili, Rao Saleem, Alice Gosselin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
435 Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma
by: Myung Ju Ahn, et al.
Published: (2021-11-01) -
481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors
by: Rui Wang, et al.
Published: (2021-11-01) -
Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis
by: Stacy Grace de Lima, et al.
Published: (2023-03-01) -
Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient
by: Tatiana Ferreira França, et al.
Published: (2024-01-01) -
Pegasus Descending /
by: Burke, James Lee
Published: (2006)